Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1988 1
1989 8
1990 3
1991 1
1992 3
1993 6
1994 3
1995 9
1996 11
1997 9
1998 6
1999 3
2000 5
2001 7
2002 5
2003 8
2004 8
2005 5
2006 5
2007 9
2008 11
2009 17
2010 15
2011 10
2012 10
2013 7
2014 13
2015 16
2016 8
2017 8
2018 8
2019 6
2020 7
2021 9
2022 10
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators. van der Heijden MS, et al. Among authors: beuzeboc p. N Engl J Med. 2023 Nov 9;389(19):1778-1789. doi: 10.1056/NEJMoa2309863. Epub 2023 Oct 22. N Engl J Med. 2023. PMID: 37870949 Clinical Trial.
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. Tagawa ST, et al. Among authors: beuzeboc p. J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30. J Clin Oncol. 2021. PMID: 33929895 Free PMC article. Clinical Trial.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Gravis G, et al. Among authors: beuzeboc p. Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8. Lancet Oncol. 2013. PMID: 23306100 Clinical Trial.
[Nausea and vomiting induced by chemotherapy].
Scotté F, Chastenet M, Leroy P, Aumont L, Goudiaby C, Legeay K, Beuzeboc P. Scotté F, et al. Among authors: beuzeboc p. Rev Prat. 2019 Jan;69(1):49-54. Rev Prat. 2019. PMID: 30983284 Review. French.
Radium 223 dichloride for prostate cancer treatment.
Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N. Deshayes E, et al. Among authors: beuzeboc p. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. doi: 10.2147/DDDT.S122417. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28919714 Free PMC article. Review.
The androgen receptor for the radiation oncologist.
Quero L, Rozet F, Beuzeboc P, Hennequin C. Quero L, et al. Among authors: beuzeboc p. Cancer Radiother. 2015 May;19(3):220-7. doi: 10.1016/j.canrad.2015.02.008. Epub 2015 Apr 23. Cancer Radiother. 2015. PMID: 25921704 Review.
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M. Salaün H, et al. Among authors: beuzeboc p. Bull Cancer. 2022 Jan;109(1):76-82. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17. Bull Cancer. 2022. PMID: 34799081 Review. French.
[Management of low-risk prostate cancer].
Rozet F, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Renard-Penna R, Richaud P, Salomon L, Soulié M; Les membres du comité de cancérologie de l’AFU. Rozet F, et al. Among authors: beuzeboc p. Prog Urol. 2015 Jan;25(1):1-10. doi: 10.1016/j.purol.2014.10.007. Epub 2014 Nov 20. Prog Urol. 2015. PMID: 25454776 Review. French.
An ethics of HPV vaccination: beyond principlism.
Stoeklé HC, Sekkate S, Ayoubi JM, Beuzeboc P, Hervé C. Stoeklé HC, et al. Among authors: beuzeboc p. Hum Vaccin Immunother. 2022 Nov 30;18(5):2082793. doi: 10.1080/21645515.2022.2082793. Epub 2022 Jun 8. Hum Vaccin Immunother. 2022. PMID: 35674781 Free PMC article. No abstract available.
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Jones RH, Fizazi K, James ND, Tammela TL, Matsubara N, Priou F, Beuzeboc P, Lesimple T, Bono P, Kataja V, Garcia JA, Protheroe A, Shore N, Aspegren J, Joensuu H, Kuss I, Fiala-Buskies S, Vjaters E. Jones RH, et al. Among authors: beuzeboc p. Prostate Cancer Prostatic Dis. 2023 Oct 26. doi: 10.1038/s41391-023-00740-9. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37884613
250 results